reports
Immunocore reports first quarter financial results and provides a busi...
Immunocore reports first quarter financial results and provides a business update Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year On track for Phase 3 TEBE-AM trial to complete enrollment in 1H 2026 On track for dose selection in Phase 3 PRISM-MEL-301 trial in 2H 2025 Initial multiple ascending dose data for HIV functional cure candidate presented during oral session at CROI 2025; dose escalation ongoing Cash, cash equivalents and marketable securities...
- Oliver Metzger
- Thomas Zlowodzki
- Wim Gille
- Oliver Metzger
- Thomas Zlowodzki
- Wim Gille
- Damien Choplain
- Martial Descoutures
- Damien Choplain
- Martial Descoutures
BioNTech veröffentlicht Ergebnisse für das erste Quartal 2025 sowie In...
BioNTech veröffentlicht Ergebnisse für das erste Quartal 2025 sowie Informationen zur Geschäftsentwicklung Weiterentwicklung der Onkologie-Pipeline vorangetrieben mit strategischem Fokus auf zwei tumorübergreifende (Pan-Tumor-)Programme: Immunmodulator-Kandidat BNT327, ein gegen PD-L1 und VEGF-A1 gerichteter bispezifischer Antikörper, und mRNA-Krebsimmuntherapie-Kandidaten BioNTechs Kombinationsstrategie in der Onkologie wurde anhand mehrerer klinischer Daten-Updates aus der Onkologie-Pipeline untermauert, unter anderem durch erste Daten für die innovative Kombination von BNT327 mit einem ...
BioNTech Announces First Quarter 2025 Financial Results and Corporate ...
BioNTech Announces First Quarter 2025 Financial Results and Corporate Update Continued oncology pipeline advancement with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator BNT327, a bispecific antibody targeting PD-L1 and VEGF-A1, and mRNA cancer immunotherapies Presented multiple clinical updates across oncology pipeline underlining BioNTech’s combination strategy in oncology with first data presented for the novel combination of BNT327 plus antibody-drug conjugates (“ADCs”) Development and commercial preparation for a 2025/2026 season variant-adapted ...
BioNTech ernennt Ramón Zapata zum neuen Finanzvorstand
BioNTech ernennt Ramón Zapata zum neuen Finanzvorstand Mainz, Deutschland, 5. Mai 2025 (GLOBE NEWSWIRE) – (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) gab heute bekannt, dass der Aufsichtsrat Ramón Zapata-Gomez mit Wirkung zum 1. Juli 2025 zum Finanzvorstand (Chief Financial Officer, „CFO“) ernannt hat. Er wechselt von der globalen biomedizinischen Forschungsorganisation der Novartis AG (Novartis Biomedical Research), wo er seit 2022 als CFO tätig war, zu BioNTech. Ramón Zapata tritt die Nachfolge von Jens Holstein an, der wie bereits angekündigt zum 30. Juni 2025 planmäßig aus dem Un...
BioNTech Announces Appointment of Ramón Zapata to Management Board as ...
BioNTech Announces Appointment of Ramón Zapata to Management Board as Chief Financial Officer Mainz, Germany, May 5, 2025 (GLOBE NEWSWIRE) – (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Ramón Zapata-Gomez to the Management Board as Chief Financial Officer (“CFO”) effective July 1, 2025. He will join BioNTech from Novartis AG’s global biomedical research organization where he has been serving as CFO since 2022. Ramón Zapata will succeed Jens Holstein, who, as previously planned and announced, will retire at the end of his term on June ...
- Jean-François Granjon
SCHP SECHE ENVIRONNEMENT
VAC PIERRE & VACANCES SA
NXI NEXITY SA CLASS A
MF WENDEL SE
TNG TRANSGENE SA
BIO BB BIOTECH AG
KORI KORIAN SA
STF STEF
ITP INTERPARFUMS
SWP SWORD GROUP SE
CGM CEGEDIM SA
VETO VETOQUINOL SA
MRN MERSEN SA
MTU MANITOU BF SA
FII LISI SA
LSS LECTRA SA
GBT GUERBET SA
CDA COMPAGNIE DES ALPES SA
ATE ALTEN SA
XIOR XIOR STUDENT HOUSING N.V.
COFB COFINIMMO SA
SAVE SAVENCIA SA
HEIJM HEIJMANS N.V. CERT
MBWS
PAL MARIE BRIZARD WINE & SPIRITS SA
GNFT PALFINGER AG
SEFER GENFIT SA
LIGHT SERGEFERRARI GROUP SA
11B SIGNIFY NV
INSD 11 BIT STUDIOS S.A.
ALR VERIMATRIX SA
SPIE ALIOR BANK SA
LFDE SPIE SA
TEC LA FRANCAISE DE L'ENERGIE SA
FTG111 TECHNIPFMC PLC
TKO FLATEXDEGIRO AG
VOS TIKEHAU CAPITAL SCA
AGR VOSSLOH AG
RBO AGRANA BETEILIGUNGS-AG
ZEL ROCHE BOBOIS INTERNATIONAL SAS
WDP PHARMA MAR SA
FUR WAREHOUSES DE PAUW SCA
FUGRO NV
- Jean-François Granjon
SCHP SECHE ENVIRONNEMENT
VAC PIERRE & VACANCES SA
NXI NEXITY SA CLASS A
MF WENDEL SE
TNG TRANSGENE SA
BIO BB BIOTECH AG
KORI KORIAN SA
STF STEF
ITP INTERPARFUMS
SWP SWORD GROUP SE
CGM CEGEDIM SA
VETO VETOQUINOL SA
MRN MERSEN SA
MTU MANITOU BF SA
FII LISI SA
LSS LECTRA SA
CDA COMPAGNIE DES ALPES SA
ATE ALTEN SA
XIOR XIOR STUDENT HOUSING N.V.
COFB COFINIMMO SA
SAVE SAVENCIA SA
HEIJM HEIJMANS N.V. CERT
MBWS
PAL MARIE BRIZARD WINE & SPIRITS SA
GNFT PALFINGER AG
SEFER GENFIT SA
LIGHT SERGEFERRARI GROUP SA
11B SIGNIFY NV
INSD 11 BIT STUDIOS S.A.
ALR VERIMATRIX SA
SPIE ALIOR BANK SA
LFDE SPIE SA
TEC LA FRANCAISE DE L'ENERGIE SA
FTG111 TECHNIPFMC PLC
TKO FLATEXDEGIRO AG
VOS TIKEHAU CAPITAL SCA
AGR VOSSLOH AG
RBO AGRANA BETEILIGUNGS-AG
ZEL ROCHE BOBOIS INTERNATIONAL SAS
WDP PHARMA MAR SA
FUR WAREHOUSES DE PAUW SCA
FUGRO NV
- Martial Descoutures
- Oussema Denguir
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
- Martial Descoutures
- Oussema Denguir
Transgene Provides Business and Financial Update for Q1 2025
Transgene Provides Business and Financial Update for Q1 2025 TG4050: Updated randomized Phase I data to be presented in Rapid Oral Presentation at ASCO 2025 Dr. Simone Steiner appointed Chief Technical Officer (CTO) Business funded until the end of April 2026 Strasbourg, France, April 24, 2025, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today provides a business update, including its financial position as of March 31, 2025. Key events and upcoming milestones Over the first quarte...
Transgene fait le point sur ses activités et sa situation financière a...
Transgene fait le point sur ses activités et sa situation financière au premier trimestre 2025 TG4050 : Communication de nouvelles données de la partie Phase I randomisée lors d’une présentation orale rapide à l’ASCO 2025 Nomination du Dr Simone Steiner, Directrice des opérations techniques (CTO) La Société est financée jusqu’à fin avril 2026 Strasbourg, France – Le 24 avril 2025, 17 h 45 – Transgene (Euronext Paris : TNG), société de biotechnologie qui conçoit et développe des immunothérapies contre le cancer reposant sur des vecteurs viraux, publie aujourd’hui un point sur son activit...
BioNTech präsentiert auf der AACR-Jahrestagung 2025 klinische und präk...
BioNTech präsentiert auf der AACR-Jahrestagung 2025 klinische und präklinische Daten zu mRNA- und Immunonkologie-Fokus-Programmen MAINZ, Deutschland, 24. April 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird auf der diesjährigen Jahrestagung der American Association for Cancer Research („AACR“), die vom 25. bis 30. April 2025 in Chicago, Illinois, stattfindet, Daten zu ausgewählten Kandidaten aus ihrer diversifizierten Onkologie-Pipeline präsentieren – unter anderem aus den Bereichen mRNA-Krebsimmuntherapien, innovativen Immunmodulatoren und zielgerichteten ...
BioNTech to Present Clinical and Preclinical Data Across mRNA and Next...
BioNTech to Present Clinical and Preclinical Data Across mRNA and Next-Generation Immuno-Oncology Priority Programs at AACR 2025 MAINZ, Germany, April 24, 2025 -- (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data for selected assets from its diversified oncology pipeline, including mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies, at the American Association for Cancer Research (“AACR”) Annual Meeting held in Chicago, Illinois from April 25-30, 2025. The oral and poster presentations underline both the progress of BioNTech’s advanced priority...
Availability of Preparatory Documents for the Combined General Meeting...
Availability of Preparatory Documents for the Combined General Meeting of May 15, 2025 Strasbourg, France, April 24, 2025, 8:00 a.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies, announced that the documentation related to the Combined General Meeting (ordinary and extraordinary sessions) of Transgene’s shareholders is available. The notice of meeting, comprising the agenda and the draft resolutions, was published in the Bulletin des Annonces Légales Obligatoires (BALO) n° 42 of April 7, 2025 and in the corrigendum no. 47 o...
Mise à disposition des documents préparatoires à l'Assemblée générale ...
Mise à disposition des documents préparatoires à l'Assemblée générale du 15 mai 2025 Strasbourg, France – Le 24 avril 2025, 08 h 00 – Transgene (Euronext Paris : TNG), société de biotechnologie qui conçoit et développe des immunothérapies du cancer reposant sur des vecteurs viraux, a mis en ligne ses documents préparatoires à l’Assemblée générale mixte (assemblée générale ordinaire et extraordinaire). L’avis de réunion valant avis de convocation comportant l’ordre du jour et les projets de résolutions a été publié au BALO (Bulletin des Annonces Légales Obligatoires) n° 42 du 7 avril 2025,...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.